This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Janssen Biotech gets rights to autoimmune/inflammation compounds from Phenex
04 Aug 2017
Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive rights to Phenex Pharmaceuticals AG’s (small-molecule therapeutics for liver disease and autoimmune/inflammatory disorders) compounds targeting the nuclear hormone receptor RORyt to treat chronic autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?